Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹943.90down ₹15.90 (1.66%)BSE ₹945.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹959.80.
28 Oct: open ₹953.30, high ₹959.80, low ₹936.40
52-week range of traded prices to 28 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,035 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.70
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 36.55
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.12
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 57,06841.5% delivered
Jubilant Pharmova board meetings
112 filed, newest first. Page 2 of 3.
Jan 2019
Oct 2018
15 Oct · Board meeting
Jul 2018
20 Jul · Board meeting
Jun 2018
22 Jun · Board meeting
May 2018
Jan 2018
Oct 2017
Jul 2017
3 Jul · Board meeting
Not held on this date
May 2017
23 May · Board meeting
Feb 2017
Jan 2017
Oct 2016
27 Oct · Board meeting
Jul 2016
May 2016
Jan 2016
Oct 2015
29 Oct · Board meeting
Jul 2015
May 2015
Jan 2015
23 Jan · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2014.
Oct 2014
20 Oct · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014.
Jul 2014
25 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014.
May 2014
16 May · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2014; (2) Recommendation of Dividend for the Year ended March 31, 2014. Further as per the Company's insider Trading Code, the trading window for dealing in the securities of the Company would remain closed for all Directors/Officers/ Designated Employees of the Company from May 19, 2014 to May 27, 2014 (both days inclusive).
Jan 2014
Oct 2013
21 Oct · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013
Jul 2013
24 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
29 May · Board meeting
8 May · Board meeting
Board of Directors of the Company in its meeting held May 07, 2013 inter alia, accorded its approval to constitute a committee to explore options and opportunities to raise debt for the Company, including by way of issue of foreign currency bonds and /or non-convertible debentures, or by any one or more or a combination of the above or otherwise, to be denominated in Indian rupees or foreign currency, as the case may be, to various eligible investors in or outside India, whether by way of a public offering or by way of a private placement, in the best interests of the Company and all its stakeholders, up to an amount not exceeding US $ 250 million for prepayment of the existing debt and other general corporate purposes without increasing the overall net debt levels of the Company.
Apr 2013
Jan 2013
21 Jan · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2012.
Oct 2012
26 Oct · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2012.
Jul 2012
13 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2012.
Apr 2012
27 Apr · Board meeting
To inter-alia consider : (1) Audited Financial Results of the Company for the year ended March 31, 2012; (2) Recommendation of Dividend for the Year ended March 31, 2012.
Jan 2012
27 Jan · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2011.
Oct 2011
24 Oct · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2011.
Aug 2011
1 Aug · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2011.
May 2011
2 May · Board meeting
To inter-alia consider : (1) Audited Financial Results of the Company for the year ended March 31, 2011; (2) Recommendation of Dividend for the Year ended March 31, 2011.
Feb 2011
4 Feb · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2010.
Nov 2010
3 Nov · Board meeting
To Inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2010.
Oct 2010
12 Oct · Board meeting
To Inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2010.
Jul 2010
19 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2010.
May 2010
3 May · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2010. (2) Recommendation of Dividend for the year ended March 31, 2010.
Jan 2010
21 Jan · Board meeting
At a meeting of the Board of Directors of the Company held on January 21, 2010, inter alia, the following decisions have been taken: 1) The Board has accorded approval for raising additional capital through issue of Equity / GDRs / ADRs / FCCBs or others equity related instruments or issue of equity or equity related instruments to Qualified Institutional Buyers (QIBs) of Rs.1000 Crores subjects to approval of members and other necessary approvals. 2) Dr Inder Mohan Verma has been appointed as additional Directors of the Company. He will be an independent director. 3) In line with the continued strategy of enhancing our focus as a Pharma and life Science Company, the Board has in principal approved the Demerger of its Agri and Performance Polymer business into a separate Company for pursuing the growth prospects of both the business independently and efficiently. The detailed Demerger Scheme is expected to be approved in the meeting to be held in the first quarter of FY 2010-11.13 Jan · Board meeting
Meeting on 21 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009/Unaudited Financial Results/Others”
Oct 2009
14 Oct · Board meeting
Meeting on 22 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009/Unaudited Financial Results/Others”